High Cost of IPF Therapies Tied to ‘Substantial Economic Burden’

High Cost of IPF Therapies Tied to ‘Substantial Economic Burden’

302512

High Cost of IPF Therapies Tied to ‘Substantial Economic Burden’

Interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), are associated with a substantial economic burden to healthcare systems due to the high cost of their treatments, a German study reported. Medication costs for IPF patients, recruited between November 2016 and April 2017 and followed for one year, rose from €1,442 (around $1,690) to €11,000 (around $12,888), with the anti-fibrotic therapies Esbriet (pirfenidone) and Ofev (nintedanib) accounting for nearly 85% of total ILD medication costs. Additional disorders,…

You must be logged in to read/download the full post.